Compare Citius Pharmaceuticals Inc (CTXR) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Plby Group Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Plby Group Inc trades at $0.97 (market cap $118.21M). The key difference: Plby Group Inc is far larger — about 8.7× Citius Pharmaceuticals Inc's market cap, and Plby Group Inc is more actively traded (919,783 versus 132,438). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Plby Group Inc for 24 Days on average.
| CTXR | PLBY | |
|---|---|---|
Market Cap | $13.62M | $118.21M |
Volume | 132,438 | 919,783 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $2.71 |
52-Week Low | $0.48 | $0.99 |
Typical Hold Time | 16 Days | 24 Days |
Enterprise Value | $3.79M | $263.80M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
PLBY trades at $1.02, down 1.92% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $12.67 million in 2025, though revenue grew to $120.93 million and the net loss narrowed significantly from prior years. Recent news highlights leadership appointments aimed at driving brand growth. The stock has a high P/E ratio of 49.34 but a reasonable P/S of 0.87, and analyst consensus is strongly bullish with 75% buy ratings.
The outlook is mixed: improving profitability trends and positive analyst sentiment offer potential upside, but high debt levels, negative shareholder equity, and bearish technicals pose significant risks. Investors should weigh the company's growth initiatives against its financial leverage and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
